Development of the Revised Opioid Risk Tool to Predict Opioid Use Disorder in Patients with Chronic Nonmalignant Pain.


Journal

The journal of pain
ISSN: 1528-8447
Titre abrégé: J Pain
Pays: United States
ID NLM: 100898657

Informations de publication

Date de publication:
07 2019
Historique:
received: 21 09 2018
revised: 20 11 2018
accepted: 22 01 2019
pubmed: 29 1 2019
medline: 9 9 2020
entrez: 29 1 2019
Statut: ppublish

Résumé

The Opioid Risk Tool (ORT) is a commonly used measure of risk of aberrant drug-related behaviors in patients with chronic pain prescribed opioid therapy. In this study, the discriminant predictive validity of the ORT was evaluated in a unique cohort of patients with chronic nonmalignant pain (CNMP) on long-term opioid therapy who displayed no evidence of developing an opioid use disorder (OUD) and a sample of patients with CNMP who developed an OUD after commencing opioid therapy. Results revealed that the original ORT was able to discriminate between patients with and without OUDs (odds ratio = 1.624; 95% confidence interval [CI] = 1.539-1.715, P < .001). A weighted ORT eliminating the gender-specific history of preadolescent sexual abuse item revealed comparable results (odds ratio = 1.648, 95% CI = 1.539-1.742, P < .001). A revised unweighted ORT removing the history of preadolescent sexual abuse item was notably superior in predicting the development of OUD in patients with CNMP on long-term opioid therapy (odds ratio = 3.085; 95% CI = 2.725-3.493; P < .001) with high specificity (.851; 95% CI = .811-.885), sensitivity (.854; 95% CI = .799-.898), positive predictive value (.757; 95% CI = .709-.799), and negative predictive value (.914; 95% CI = .885-.937). Perspective: The revised ORT is the first tool developed on a unique cohort to predict the risk of developing an OUD in patients with CNMP receiving opioid therapy, as opposed to aberrant drug-related behaviors that can reflect a number of other issues. The revised ORT has clinical usefulness in providing clinicians a simple, validated method to rapidly screen for the risk of developing OUD in patients on or being considered for opioid therapy.

Identifiants

pubmed: 30690168
pii: S1526-5900(18)30622-9
doi: 10.1016/j.jpain.2019.01.011
pmc: PMC6768552
mid: NIHMS1522271
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

842-851

Subventions

Organisme : NIDA NIH HHS
ID : R01 DA032776
Pays : United States
Organisme : NIDA NIH HHS
ID : R21 DA046364
Pays : United States

Informations de copyright

Copyright © 2019 the American Pain Society. Published by Elsevier Inc. All rights reserved.

Références

Arch Gen Psychiatry. 2000 Oct;57(10):953-9
pubmed: 11015813
Pain. 2004 Nov;112(1-2):65-75
pubmed: 15494186
Pain Med. 2005 Nov-Dec;6(6):432-42
pubmed: 16336480
J Pain. 2006 Sep;7(9):671-81
pubmed: 16942953
Pain. 2007 Jul;130(1-2):144-56
pubmed: 17493754
J Pain. 2009 Feb;10(2):113-30
pubmed: 19187889
J Pain. 2009 Feb;10(2):147-59
pubmed: 19187891
Pain Med. 2009 Nov;10(8):1426-33
pubmed: 20021601
Adv Psychosom Med. 2011;30:61-91
pubmed: 21508626
Clin J Pain. 2012 Feb;28(2):93-100
pubmed: 21750461
J Opioid Manag. 2011 Sep-Oct;7(5):347-51
pubmed: 22165033
J Opioid Manag. 2013 Jan-Feb;9(1):19-27
pubmed: 23709300
Pain. 2013 Nov;154(11):2324-34
pubmed: 24148704
J Opioid Manag. 2013 Sep-Oct;9(5):315-24
pubmed: 24353044
J Opioid Manag. 2014 Sep-Oct;10(5):353-64
pubmed: 25350477
J Pain. 2015 May;16(5):389-411
pubmed: 25660826
J Opioid Manag. 2015 Mar-Apr;11(2):171-83
pubmed: 25901482
MMWR Recomm Rep. 2016 Mar 18;65(1):1-49
pubmed: 26987082
CMAJ. 2017 May 8;189(18):E659-E666
pubmed: 28483845
J Pain Res. 2017 May 03;10:979-987
pubmed: 28496354
Drug Alcohol Depend. 2017 Jul 1;176:89-95
pubmed: 28531769
Front Public Health. 2017 Sep 07;5:237
pubmed: 28936431
Anesth Analg. 2017 Nov;125(5):1741-1748
pubmed: 29049118
Transl Behav Med. 2018 Mar 1;8(2):305-308
pubmed: 29385551
Pain Med. 2018 Feb 2;:null
pubmed: 29408996
Am J Prev Med. 1998 May;14(4):245-58
pubmed: 9635069
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538

Auteurs

Martin D Cheatle (MD)

Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: cheatle@pennmedicine.upenn.edu.

Peggy A Compton (PA)

Department of Family and Community Health, School of Nursing, University of Pennsylvania, Philadelphia, Pennsylvania.

Lara Dhingra (L)

MJHS Institute for Innovation in Palliative Care, New York, New York; Albert Einstein College of Medicine, Bronx, New York.

Thomas E Wasser (TE)

Consult-Stat: Complete Statistical Services, Macungie, Pennsylvania.

Charles P O'Brien (CP)

Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH